The field of traditional medicine, with its deep historical roots, offers a multitude of natural compounds with potential therapeutic benefits. Lately, ...
From a seasonal cold to a stomach bug, nobody likes catching a virus — and epidemics can be devastating. We need safe, sustainable antiviral options to treat the outbreaks of the future. Scientists in ...
Pharmaceutical Technology on MSN
MSD bets big on flu antivirals with $9.2bn buyout of Cidara
MSD has now agreed two deals around the $10bn mark in 2025 as it looks to shore up its pipeline with Keytruda’s looming ...
SHELTON, CONNECTICUT / ACCESS Newswire / November 14, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the “Company”), a clinical stage leader developing revolutionary broad-spectrum antiviral drugs ...
A Food and Drug Administration advisory committee voted Tuesday in favor of recommending molnupiravir, a new antiviral pill made by the drug companies Merck and Ridgeback Biotherapeutics, for treating ...
7h
NanoViricides, Inc. Has Filed its Quarterly Report – Subsequent Raise Has Fortified Fiscal Position
SHELTON, CONNECTICUT / ACCESS Newswire / November 17, 2025 / NanoViricides, Inc. (NYSE Amer.:NNVC) (the “Company”), reports that it has filed its Quarterly Report on Form 10-Q for the fiscal quarter ...
The rollout of the US government's Covid-19 test-to-treat program is underway, with in-pharmacy clinics ordering shipments of Covid-19 antiviral medications, and some locations expecting to offer the ...
As the toll from the COVID-19 pandemic continued to mount, antiviral medications such as Paxlovid were hailed by health officials as an important way to reduce the risk of severe illness or death. Yet ...
SHELTON, CONNECTICUT / ACCESS Newswire / November 10, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the “Company”) today ...
Despite a recent capital raise, Shelton-based antiviral drug developer NanoViricides Inc. disclosed it does not have enough cash to fund operations beyond mid-February and will need additional ...
Background The large-scale deployment of antiviral drugs from the Strategic National Stockpile during the 2009 H1N1 influenza response provides a unique opportunity to study local public health ...
Received FDA IND clearance to evaluate CDI-988 as both norovirus preventive and treatmentExpects to initiate CDI-988 Phase 1b ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback